Study S002209

The Effect of the GLP-1 Analogue Exenatide on Glucose Metabolism in the CNS and Heart During Hyperglycemia in Type-2 Diabetic Patients Assessed by PET

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00747968
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 8
Start: 2010-02
Primary completion: 2010-11
Lead sponsor: University of Aarhus
Conditions: Type 2 Diabetes
Interventions: DRUG:Byetta, Exenatide
Results posted: FALSE

Registered primary outcomes

steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo. [oct. 2008 - oct 2010]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021573	Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. Gejl M, The Journal of clinical endocrinology and metabolism	2012	Randomized trial	PMID 22544917 DOI	cites ClinicalTrials.gov:NCT00747968; registry reference DERIVED:22544917